INDIVIOR PHARMACEUTICALS INC (INDV)
Health Care · specialty pharmaceuticals · NASDAQ
A pharmaceutical company specialized in innovative treatments for substance use and mental health disorders.
What INDIVIOR PHARMACEUTICALS INC does
Indivior Pharmaceuticals is a pharmaceutical company focused on developing and commercializing treatments for substance use disorders and mental health conditions. Its business is built on a portfolio of therapies for opioid use disorder and other related conditions. The company is actively pursuing growth through internal development and potential strategic acquisitions, such as its proposed merger with Supernus Pharmaceuticals.
Themes: substance use disorder treatment, mental health, specialty pharmaceuticals
Fundamentals
- Price$34.77 as of 2026-10-20 close
- Market cap$4.1B as of 2026-07-28 (share count; price 2026-10-20)
- 1-year return+43.1% 2025-10-20 close $24.29 → 2026-10-20 close $34.77
- P/E12.46 as of 2026-10-20
- Net margin+16.9% FY2025, SEC XBRL
- Gross margin+80.2% FY2025, SEC XBRL
- ROICn/a No figure: its stockholders' equity is zero or negative.
- Debt / equityn/a No figure: its stockholders' equity is zero or negative, where the ratio means nothing.
- Revenue growth (YoY)+4.3% FY2025, SEC XBRL
- Revenue CAGR (3y)+11.2% SEC XBRL
- Beta0.77 as of 2026-09-02
- Last reported earnings2026-08-03 SEC EDGAR Form 8-K (Item 2.02)
How INDV compares in its sector
- price-to-earnings ratiobottom 25% 181 covered Health Care peers, as of 2026-10-20
- net profit margintop 25% 430 covered Health Care peers, as of 2026-09-02
- operating margintop 25% 417 covered Health Care peers, as of 2026-09-02
- gross margintop 25% 189 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
INDV is not currently in any published Top 10 list. Its scores are below.
Top 10 score
60.5 #206 of 1,265 scored · #28 of 146 in Health Care
Valuation 93rd (price to earnings 12.5 (within its sector)) and capital return 83rd (net share count bought back over the year 3.8); weakest is financial health (10th, free cash flow margin -7.5%).
Scores as of 20 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Quarterly results
| Quarter | Revenue | Gross profit | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $343M | $294M | $160M | $122M | $0.98 | $229M† | $7M† |
| Q1 FY2026 2026-03-31 | $317M | $277M | $137M | $89M | $0.69 | -$9M | $20M |
| Q4 FY2025 2025-12-31 | $358M† | $292M† | $81M† | $102M† | $0.79† | -$221M† | $24M† |
| Q3 FY2025 2025-09-30 | $314M | $230M | $43M | $42M | $0.33 | -$39M† | $20M† |
| Q2 FY2025 2025-06-30 | $302M | $250M | $72M | $18M | $0.14 | $158M† | $17M† |
| Q1 FY2025 2025-03-31 | $266M | $221M | $66M | $47M | $0.38 | $75M | $5M |
| Q4 FY2024 2024-12-31 | $299M† | $250M† | $46M | $21M | $0.16† | -$17M† | $16M† |
| Q3 FY2024 2024-09-30 | $307M | $241M | $35M | $22M | $0.16 | $2M† | $7M† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$222M
- Total debt$487M borrowings only; leases excluded
- Net debt$265M total debt − cash − short-term investments
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How INDIVIOR PHARMACEUTICALS INC looks technically
INDIVIOR PHARMACEUTICALS INC (INDV) is trading 2.6% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 344 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 47, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 5 trading days ago (its momentum flipped negative). It made a new 20-day low about 3 trading days ago. It is 18.8% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 2.6% below its 200-day average, the long-term trend line — a long-term downtrend | -2.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $35.81 | $35.81 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $35.69 | $35.69 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 21 calendar days ago — the swings before that are what the structure reading is measured on | 21 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 37.05. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 344 trading days ago — a "golden cross", a bullish long-term signal | 344 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with sellers in control | 26.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 47, neither overbought (above 70) nor oversold (below 30) | 47.2 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($32.31 to $36.35) — its "stochastic" reading is 61 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 60.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 5 trading days ago (its momentum flipped negative) | 5 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $42.81 | $42.81 |
|---|---|---|
| From the 52-week high | it is 18.8% below its 52-week high (its highest price of the past year) | -18.8% |
| Above the 52-week low | it is 47.6% above its 52-week low (its lowest price of the past year) | +47.6% |
| Below the 52-week high | it is 18.8% below its highest point of the past year | 18.8% |
| Since a 20-day breakout | it made a new 20-day low about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day low about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $42.81 (set on 2026-06-26) | $42.81 |
| Given back of the 52-week move | over the past year its closes ranged ($23.87 to $41.83), and it has given back roughly a third of its rise from last year’s low — 39% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $30.16 to $30.73. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 39.3% |
| From the all-time high | it is 18.8% below its all-time high | -18.8% |
| Nearest price level | it is trading 2.0% below a resistance level at $35.46 — a price it turned at six times since 2025-12-16, most recently on 2026-08-04. Since 2024-10-21 it has 8 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +2.0% |
| All-time low | its lowest closing price on record is $1.75 (set on 2019-04-10) | $1.75 |
| Above the all-time low | it is 1886.9% above its all-time low | +1,887% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 39th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.19 between its high and its low — about 3.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.19 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $33.26 and $37.52 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $33.26 – $35.39 – $37.52 |
| Typical daily range (% of price) | its price moves about 3.4% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.4% |
| Stretch from the 200-day average | it is trading 0.8 daily ranges below its 200-day average price (2.6% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.8 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.81× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
3
| Since a doji | 6 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 6 sessions ago |
|---|---|---|
| Since a bullish engulfing | 7 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 7 sessions ago |
| Since a bearish engulfing | 5 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 5 sessions ago |
Price gaps
1
| Gap at the open | it opened on 2026-10-20 0.4% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.4% |
|---|
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +7.15% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 1.3 percentage points (the stock lost 0.3% while the market gained 1.0%) | -1.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 14.8 percentage points (the stock lost 11.1% while the market gained 3.6%) | -14.8% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 1.3 percentage points (the stock gained 7.2% while the market gained 8.5%) | -1.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 28.6 percentage points (the stock gained 43.1% while the market gained 14.6%) | +28.6% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 2.8% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 6.0% of the share price. | -2.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 2% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $35.41 — a volume-weighted average of daily closes over 196 sessions, not a true tick-by-tick VWAP. | -1.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% below the average price paid since it last reported on 2026-08-03 (its 10-Q), so the typical buyer over that stretch is under water. That average is $36.08 — a volume-weighted average of daily closes over 56 sessions, not a true tick-by-tick VWAP. | -3.6% |
Channel down, bearish — forming · entry $32.25 · 80 sessions in
Price levels it has turned at before
INDV last closed at $34.77 on 2026-10-20. Since 2024-10-21 it has turned at 8 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $35.46 | Resistance | 2.0% above the last close | turned there six times · 2025-12-16 to 2026-08-04 |
| $36.33 | Resistance | 4.5% above the last close | turned there three times · 2025-12-22 to 2026-10-08 |
| $32.41 | Support | 6.8% below the last close | turned there twice · 2025-11-06 to 2026-06-02 |
| $37.77 | Resistance | 8.6% above the last close | turned there three times · 2025-12-08 to 2026-06-22 |
| $29.39 | Support | 15.5% below the last close | turned there twice · 2025-11-14 to 2026-03-12 |
| $25.05 | Support | 28.0% below the last close | turned there twice · 2025-08-27 to 2025-09-08 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $37.05.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $26.92 and $30.79 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $37.05.
This reading has stood for 11 trading days, since 2026-10-06.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Broke down to a new 20-day low · MACD just crossed bearish (12/26/9) · Under water since its last earnings report (below the anchored VWAP) · Trading below the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$49.00 range $43.00 – $53.00; median $50.00
Analyst estimates, as of 2026-10-16. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for INDV
- Consensus EPS estimate$1.12 next reporting period, as of 2026-10-16
- Estimate change, 30 days$0.00 (0.0%) from $1.12, on 2026-09-11, 35-day window
- Readings revised upward0% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on a concentrated portfolio of products for substance use disorders and associated revenue volatility.","Risks related to the successful integration and realization of anticipated synergies from the proposed merger with Supernus.","Potential for increased competition, evolving regulatory environments, and ongoing litigation risks."]
What changed in the latest 10-Q
AI-assisted comparison of INDV's 10-Q filed 2026-08-03 against the prior one filed 2026-04-30.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-03) adds disclosure of an Agreement and Plan of Merger with Supernus entered into August 1, 2026, expected to close during the fourth quarter of 2026, with reference to Note 15. Subsequent Events.
- Newer filing (2026-08-03) adds disclosure that during the six months ended June 30, 2026, Indivior decided to cease Phase 3 development of INDV-6001 and not advance INDV-2000 internally, and that the Company is not currently pursuing any pipeline activities.
- Newer filing (2026-08-03) adds disclosure of severance recognized during the three months ended June 30, 2026 of approximately $6 million, including approximately $5 million associated with the decisions not to advance the two research and development pipeline programs.
- Newer filing (2026-08-03) adds disclosure that during the three months ended June 30, 2026, the Company repurchased 4,664,540 shares at an average price of $37.52 for total consideration of $175 million.
- Newer filing (2026-08-03) adds disclosure that Indivior has $100 million remaining under the share repurchase program.
- Newer filing (2026-08-03) adds U.S. SUBLOCADE net revenue, U.S. Film/other net revenue, U.S. PERSERIS net revenue, Total U.S. net revenue, Rest of the World net revenue, Total SUBLOCADE net revenue, and total net revenue figures for the three and six months ended June 30, 2026 and June 30, 2025.
- Newer filing (2026-08-03) adds discussion of Rest of the World net revenue decrease for six months ended June 30, 2026, specifically a decrease of $2 million compared to the same period of 2025.
- Newer filing (2026-08-03) adds disclosure that accrued rebates and product returns and prompt pay discounts were higher in the prior-year period ending June 30, 2025.
- Removed:
- Older filing (2026-04-30) includes a section titled 'Research & Development Pipeline Updates' with detailed disclosures on INDV-6001 and INDV-2000, including that INDV-2000 did not meet its primary endpoint and additional supportive analyses; this section is not present in the newer filing.
- Older filing (2026-04-30) discloses $14 million of costs associated with the Indivior Action Agenda incurred during the three months ended March 31, 2026; this disclosure is not present in the newer filing.
- Older filing (2026-04-30) discloses that the Company entered Phase II - Accelerate of the Action Agenda; this disclosure is not present in the newer filing.
- Older filing (2026-04-30) discloses the completion of a $500 million offering of 0.625% convertible senior notes due 2031 and repayment in full of the $333 million original term loan balance; this disclosure is not present in the newer filing.
- Older filing (2026-04-30) discloses that Indivior had $275 million remaining under the share repurchase program; this disclosure is not present in the newer filing.
- Older filing (2026-04-30) discloses specific Rest of the World revenue of approximately $5 million related to market exits that are not expected to recur at that level; this disclosure is not present in the newer filing.
- Reworded:
- Overview description changed from 'predominantly the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders' (2026-04-30) to 'predominantly the manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and OUD' (2026-08-03).
- SUBLOCADE revenue concentration percentages updated from 73% and 66% for the three months ended March 31, 2026 and 2025 (2026-04-30) to 74% and 74% for the three and six months ended June 30, 2026, and 69% and 68% for the three and six months ended June 30, 2025 (2026-08-03).
- Other buprenorphine-based sublingual products revenue concentration percentages updated from 25% and 32% for the three months ended March 31, 2026 and 2025 (2026-04-30) to 25% and 25% for the three and six months ended June 30, 2026, and 27% and 29% for the three and six months ended June 30, 2025 (2026-08-03).
- SUBOXONE Film BMAT average share percentage context updated from the three months ended March 31, 2026 and 2025 (2026-04-30) to the three months ended June 30, 2026 and 2025 (2026-08-03).
- Share repurchase program disclosure updated: older filing discusses repurchase activity only for the three months ended March 31, 2026, while newer filing cumulatively discusses repurchase activity for both the three months ended March 31, 2026 and June 30, 2026.
- Note reference for litigation discussion changed from Note 12. Commitments and Contingencies (2026-04-30) to Note 13. Commitments and Contingencies (2026-08-03).
- Net revenue reporting period changed from three months ended March 31 (2026-04-30) to three and six months ended June 30 (2026-08-03), with corresponding changes in all revenue figures.
- U.S. net revenue from SUBLOCADE growth driver narrative changed from dispense unit volume growth of 20% and favorable price mix (2026-04-30) to dispense unit volume growth of 18% and 19%, gross-to-net benefits and favorable price mix (2026-08-03).
- U.S. net revenue from other products narrative changed from decline of $4 million reflecting lower category share, partially offset by favorable gross-to-net adjustments (2026-04-30) to an increase of $2 million in Q2 2026 and a decrease of $2 million in H1 2026, with both periods benefiting from favorable Film gross-to-net adjustments offset by a decline in U.S. Film category share (2026-08-03).
- Rest of the World net revenue narrative changed from an increase of $1 million including about $5 million of non-recurring market-exit revenue (2026-04-30) to a decrease of $3 million and $2 million for three and six months reflecting exit from certain non-U.S. markets (2026-08-03).
- Accrued rebates table period changed from the three months ended March 31, 2026 and 2025 (2026-04-30) to the six months ended June 30, 2026 and 2025 (2026-08-03), with corresponding changes in all figures.
- Accrued rebates explanation changed from closing balance as of March 31, 2026 of $555 million versus $678 million as of March 31, 2025 (2026-04-30) to closing balance as of June 30, 2026 of $613 million versus $712 million as of June 30, 2025 (2026-08-03).
- Notes:
- The newer filing excerpt appears truncated at the end of the accrued rebates discussion, so changes in that section may not be fully captured.
- The older filing excerpt appears truncated mid-sentence in the final accrued rebates description, so the full older wording may not be available for comparison.
Risk Factors
- Added:
- Newer filing (2026-08-03) adds a new risk factor section titled 'Risks Related to the Pending Merger with Supernus' containing multiple merger-related risk factors.
- Newer filing (2026-08-03) adds a risk factor about the merger being subject to conditions that may not be satisfied or completed on a timely basis, and the potential adverse effects of failure to complete the merger.
- Newer filing (2026-08-03) adds a risk factor stating that the exchange ratio of 1.5401 shares of Indivior common stock per share of Supernus common stock is fixed and will not be adjusted for stock price changes.
- Newer filing (2026-08-03) adds a risk factor about business uncertainties and contractual restrictions while the merger is pending that could adversely affect each party's business.
- Newer filing (2026-08-03) adds a risk factor stating that following the merger, the combined company board will consist of eight directors, four designated by Indivior and four by Supernus, which may affect future decisions.
- Newer filing (2026-08-03) adds a risk factor stating that even if the merger is completed, the company may fail to realize anticipated benefits, synergies, growth, profitability, cash flow generation, and earnings accretion.
- Newer filing (2026-08-03) states in the introductory risk factor paragraph that risk factors are 'as updated by Part II, Item 1A, Risk Factors, of the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026', and that the following risk factor is added.
- Removed:
- Older filing (2026-04-30) discloses removal of two risk factors: 'Our term loan contains covenants that limit our ability to plan for or respond to changes in our business' and 'Clinical trials for the development of products may be unsuccessful'.
- Reworded:
- The introductory statement about risk factors changed: older filing (2026-04-30) states 'There have been no material changes... with the exception that the following risk factors are removed...'; newer filing (2026-08-03) states 'There have been no material changes... as updated by Part II, Item 1A... of the Company's Quarterly Report... except that we add the following risk factor...'
- The share repurchase table period and amounts changed: older filing (2026-04-30) reports quarter ended March 31, 2026 with periods Jan-Feb-Mar, 3,974,153 shares at $31.45 average price, $400 million authority, $275 million remaining; newer filing (2026-08-03) reports quarter ended June 30, 2026 with periods April-May-June, 4,664,540 total shares repurchased (3,717,473 in May at $37.52 and 947,067 in June at $37.52), $100 million remaining.
- Footnote on average price per share changed: older filing (2026-04-30) has no separate average price footnote for March; newer filing (2026-08-03) notes the $37.52 average price represents the average across the accelerated share repurchase program initiated in May 2026 and completed in June 2026.
- Footnote on maximum shares available changed: older filing (2026-04-30) includes only the sentence 'Reflects the dollar value of shares in millions that might be repurchased under the $400 million authority announced by the Board of Directors and announced on February 26, 2026.' Newer filing (2026-08-03) has an expanded footnote 2 explaining the February 2026 $400 million authorization, $125 million repurchased during Q1 2026 leaving $275 million, an additional $175 million repurchased under an accelerated share repurchase agreement during Q2 2026, and $100 million remaining.
- Notes:
- The newer filing excerpt ends mid-sentence in footnote 2 ('As of June 30, 2026, $100 million remained available for futu...'), so the complete text of this footnote was not available.
- The older filing excerpt includes items 2 through 6 and exhibits that are not fully present in the newer excerpt, so a complete item-by-item comparison of Items 2-6 was not possible.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
2 open-market purchases and 0 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 90 days · read to 2026-10-162 buys ($107955) · 0 sells — 1 buying insider
- Last 180 days · read to 2026-10-162 buys ($107955) · 3 sells ($3M) — 1 buying, 2 selling insiders
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-27. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about INDV's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding INDV as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 29,910,153
- Reported value $1,227,213,585
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about INDV's institutional holders → See what each manager we track holds →
Short interest (FINRA)
INDV had 10,413,493 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
INDV had 8.82% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.26 days to cover at the same settlement.
- Reported short interest (shares) 10,413,493
- Short interest (% of shares outstanding) 8.82%
- Prior settlement (shares) 11,172,005
- Reported change -6.79%
- Days to cover (reported) 5.26
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Alkermes (ALKS)
- BioDelivery Sciences International
- Orexo AB
- Titan Pharmaceuticals
- Supernus Pharmaceuticals (SUPN)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare INDV vs…
Frequently asked questions
What does INDIVIOR PHARMACEUTICALS INC (INDV) do?
Indivior Pharmaceuticals is a pharmaceutical company focused on developing and commercializing treatments for substance use disorders and mental health conditions. Its business is built on a portfolio of therapies for opioid use disorder and other related conditions. The company is actively pursuing growth through internal development and potential strategic acquisitions, such as its proposed merger with Supernus Pharmaceuticals.
What sector is INDIVIOR PHARMACEUTICALS INC (INDV) in?
INDIVIOR PHARMACEUTICALS INC (INDV) is classified in the Health Care sector. Its industry is specialty pharmaceuticals. It trades on NASDAQ.
Who are INDIVIOR PHARMACEUTICALS INC's (INDV) competitors?
Notable peers of INDIVIOR PHARMACEUTICALS INC (INDV) include Alkermes, BioDelivery Sciences International, Orexo AB, Titan Pharmaceuticals and Supernus Pharmaceuticals. This peer set is informational only — not financial advice.
Is INDIVIOR PHARMACEUTICALS INC (INDV) overbought or oversold right now?
INDIVIOR PHARMACEUTICALS INC (INDV) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 47, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on INDV come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.